Book Value per Share: auriniapharma.com (AUPH)

Graphic logo of Aurinia Pharmaceuticals (AUPH)

The Aurinia Pharmaceuticals (AUPH) price chart reflects the dynamics of a biopharmaceutical player that developed the first licensed therapy for systemic lupus erythematosus, ensuring steady sales. The 4.66 metric accompanies the market launch of lupus nephritis treatments, which occupy an untapped niche with long-term demand. Geographic reach is expanding through partnerships in Asia and Europe, mitigating risks associated with the US region.

Aurinia Pharmaceuticals Inc (AUPH): Share Book Value from 07/04/2022 to 10/29/2026

auriniapharma.com - analytical breakdowns and key metrics (AUPH)

- price and consensus price forecast:
Price Chart Aurinia Pharma|AUPH - Forecast Levels Chart
- market capitalization data:
Market Capitalization Aurinia Pharmaceuticals Inc.|AUPH - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Aurinia Pharmaceuticals|AUPH - Net Asset Value|Market Capitalization to Book Value Ratio auriniapharma.com|AUPH - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Aurinia Pharmaceuticals|AUPH - Long-Term Debt to Capital|Short-Term Debt to Equity Aurinia Pharmaceuticals Inc.|AUPH - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Aurinia Pharmaceuticals Inc.|AUPH - Company Long-Term Liabilities|Company Short-Term Debts Aurinia Pharmaceuticals
Fundamental company valuation:Aurinia Pharma - AUPH
Manufactured products of Aurinia Pharmaceuticals Inc.

For Aurinia Pharmaceuticals (AUPH), the book value per share chart reflects the dynamics of the issuer's net equity. This indicator is calculated by dividing the difference between all assets and liabilities by the number of outstanding shares. Growth in this metric confirms the strengthening of the company's financial foundation. Under current conditions, the expansion of insurance coverage and demand for the nephritis treatment drug facilitate resource accumulation. This positive trend indicates an increase in the business's intrinsic value.

Competitors of Aurinia Pharmaceuticals (AUPH)

Net Assets per Single Share Argenx|BNTX - Share Book Value|Book Value per Share Abivax Corp ABVX|ADMA (admabiologics.com) - Accounting Value of a Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Kiniksa Pharmaceuticals Ltd (KNSA) - Book Value per Share|Accounting Value of a Share Grifols Biemat (GRFS)|Book Value per Share ADPT (Adaptive Biotechnologies)|celldex.com - Book Value per Share|Net Assets per Single Share BioCryst Pharmaceuticals (BCRX)|VERA: Accounting Value of a Share|DNTH (Dianthus Pharma) - Net Assets per Single Share|Pharvaris Pharma (PHVS) - Accounting Value per Share|ABCL (AbCellera Biologics Inc) - Book Value per Share|Book Value per Share tourmalinebio.com (TRML)|Precigen (PGEN) - Accounting Value per Share|Accounting Value of a Share Pharming Group NV (PHAR)|Book Value per Share NKTR|Upstream Pharma - Net Assets per Share|ZBIO: Net Assets per Single Share|IMNM: Accounting Value per Share|GOSS (Gossamer Bio) - Net Assets per Single Share|Accounting Value per Share KalVista Pharma|SEPN (Septerna Corp) - Accounting Value per Share|Book Value per Share PVLA|Net Assets per Single Share Savara Inc. SVRA|Equity per Share rigel.com (RIGL)|ANAB: Book Value per Share|Net Asset Value per Share Astria Therapeutics Inc ATXS|enGene Bio - Book Value per Share|RAPT Therapeutics Inc. (RAPT) - Book Value per Share|JBIO: Accounting Value per Share|ACRS (aclaristx.com) - Book Value per Share|KYTX - Net Assets per Single Share|Accounting Value of a Share Tiziana Life Sciences Ltd.|CABA (Cabaletta Bio, Inc) - Book Value per Share|Net Assets per Share VTYX (Ventyx Biosciences, Inc)|THTX - Net Assets per Single Share|Equity per Share avalotx.com AVTX|Book Value per Share ELDN (Eledon Pharmaceuticals, Inc.)|AGEN - Net Assets per Share|CLYM: Book Value per Share|Book Value per Share Zura Bio Ltd|ATYR - Accounting Value per Share|Accounting Value of a Share ADAG|IMA - Net Assets per Single Share|Share Book Value shattucklabs.com (STTK)|Book Value per Share Equillium|Accounting Value of a Share Connect Biopharma Holdings CNTB|Immunic Inc - Book Value per Share|ATRA: Book Value per Share|Net Assets per Single Share inflarx.de IFRX|XFOR (X4 Pharmaceuticals Inc.) - Accounting Value of a Share|Net Assets per Single Share ACET|Accounting Value per Share Celularity Corp|Book Value per Share INMB|Book Value per Share barinthusbio.com (BRNS)|Kezar Life Sciences, Inc. - Book Value per Share|Accounting Value per Share SAB Biotherapeutics Inc. SABS|AKTX (Akari Therapeutics plc) - Book Value per Share|Enlivex Therapeutics (ENLV) - Net Asset Value per Share|QTTB: Accounting Value per Share|Book Value per Share geovax.com|Edesa Biotech (EDSA) - Accounting Value per Share|Book Price of a Share iBio Inc|CARM (Carisma Therapeutics) - Book Value per Share|Net Assets per Share XTL Bio (XTLB)|Bolt Biotherapeutics, Inc. - Book Value per Share|Accounting Value per Share HCW Biologics, Inc. HCWB|Aptevo - Book Value per Share|AIM: Book Value per Share|aditxt.com (ADTX) - Net Assets per Single Share|GRI (GRI Bio Corporation) - Net Assets per Single Share|XRTX: Net Assets per Single Share|Net Assets per Share reshapelifesciences.com|Book Value per Share REVB|Book Value per Share Indaptus Therapeutics Inc INDP|Accounting Value per Share SCNI (Scinai)|CalciMedica Inc - Book Value per Share|Net Assets per Single Share Affimed Therapeutics|ALLK - Share Book Value|Book Value per Share hookipapharma.com HOOK|IGMS (IGM Biosciences) - Accounting Value of a Share|Net Assets per Single Share iTeos ITOS|Share Book Value Ocean Biomedical Corp|TC Biopharm (TCBP) - Book Value per Share|Accounting Value of a Share thirdharmonicbio.com (THRD)